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Abstract: The Human Leukocyte Antigen class I (HLA-I) system is an essential part of the immune
system that is fundamental to the successful activation of cytotoxic lymphocytes, and an effective
subsequent immune attack against both pathogen-infected and cancer cells. The importance of
cytotoxic T cell activity and ability to detect foreign cancer-related antigenic peptides has recently
been highlighted by the successful application of monoclonal antibody-based checkpoint inhibitors
as novel immune therapies. Thus, there is an increased interest in fully characterising the repertoire
of peptides that are being presented to cytotoxic CD8+ T cells by cancer cells. However, HLA-I is
also known to be present on the surface of extracellular vesicles, which are released by most if not all
cancer cells. Whilst the peptide ligandome presented by cell surface HLA class I molecules on cancer
cells has been studied extensively, the ligandome of extracellular vesicles remains relatively poorly
defined. Here, we will describe the current understanding of the HLA-I peptide ligandome and its
role on cancer-derived extracellular vesicles, and evaluate the aspects of the system that have the
potential to advance immune-based therapeutic approaches for the effective treatment of cancer.
Keywords: HLA-1; extracellular vesicles; immunopeptidome; antigen presentation; mass spectrometry;
cancer immunology
1. Extracellular Vesicles
Extracellular vesicles (EVs) have recently become of notable interest due to their role
in the mediation of intercellular communication and, in particular, their role in cancer [1]. It
has been demonstrated that EVs play a role in a large majority of cancer progression steps.
However, there is still a lack in understanding as to the extent of their function in these
processes, and which cancer-specific pathways impact upon EV biogenesis and function [2].
The biogenesis of EVs is variable and results in different categories of vesicles, including
microvesicles, apoptotic bodies and exosomes [3]. The size range of EVs is wide, typically
encompassing between 30–1000 nm, but most work has been carried out on populations
in the 50–200 nm range. Microvesicles are formed by the direct outward budding of the
plasma membrane and are slightly larger EVs with a size range of 150–1000 nm, whilst
apoptotic bodies are formed during the process of fragmentation that occurs to cells during
programmed cell death and results in the largest class of EVs at 1000–5000 nm [4]. Exosomes
are the smallest of the populations at around 40–150 nm, formed via the inward budding
of endosomal membranes, resulting in the formation of multivesicular bodies (MVBs).
These MVBs contain intralumenal vesicles, which are released upon fusion with the plasma
membrane as exosomes (Figure 1) [5]. The content of EVs varies substantially and is largely
dependent on their cell of origin, however, they are capable of carrying various proteins,
lipids, DNA and RNAs [6].
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Under homeostatic conditions, EVs aid the process of intercellular communication 
through the transference of their contents between cells, resulting in behavioural changes 
of the recipient cells [7]. Additionally, EVs have been shown to be involved in a vast num-
ber of pathological and physiological processes and have also been implicated in the de-
velopment of a number of neurological and cardiovascular diseases [8]. However, in the 
context of this current review it is significant that they are involved in almost every step 
of progression required for the development of carcinomas from the initial stage of the 
primary tumour through to metastasis. Numerous studies have now confirmed that there 
is a distinct difference between normal cell exosomes and cancer cell exosomes, both in 
terms of their content and the rate at which they are released [9–11]. 
 
Figure 1. Representation of the several routes known for extracellular vesicle (EV) biogenesis. EVs 
can be released in the form of microvesicles generated from the outward budding of the plasma 
membrane, or as exosomes through the fusion of multivesicular bodies (MVB) from within the en-
dosomal/lysosomal pathway with the plasma membrane. MVBs can alternatively degrade their 
cargo by fusing with lysosomes. Similar to that of microvesicles, apoptotic bodies are also released 
by outward budding in cells that are undergoing apoptosis. 
The content of tumour-derived EVs is diverse, can vary considerably and is largely 
dependent on the cell of origin, in a similar manner to normal cell EVs. However, the 
contents are highly bioactive and are able to elicit a considerable change in the activity of 
the recipient cells. Some of the molecules carried by cancer-derived EVs include oncopro-
teins and oncopeptides, as well as various RNA and DNA species that have the capacity 
to instigate substantial changes to the tumour microenvironment. These changes often aid 
the progression of tumour and metastasis development as EVs have been known to fea-
ture a role in aspects of invasion and the maintenance of angiogenesis [12–14]. EVs have 
been described to release factors involved in the epithelial to mesenchymal transition pro-
cess via stimulation of the epithelial cells, resulting in increased angiogenesis, extracellu-
lar matrix remodelling and the loss of adhesion of tumour cells. This change in the micro-
environment encourages the release of tumour cells into circulation whereby they have 
the ability to travel to alternative locations within the host and form metastases [14]. Ad-
ditionally, EVs have the ability to contribute towards the development of an aggressive 
Figure 1. Representation of the several routes known for extracellular vesicle (EV) biogenesis. EVs
can be released in t e form of microvesi les generated from the outward budding of the plasma
membrane, or as exosomes through the fusion of multivesicular bodies (MVB) from within the
endosomal/lysosomal pathway with the plasma membrane. MVBs can alternatively degrade their
cargo by fusing with lysosomes. Similar to that of microvesicles, apoptotic bodies are also released
by outward budding in cells that a e u dergoing poptosis.
Under homeostatic conditions, EVs aid the process of intercellular communication
hrough the transfer nce of their contents b twe n cells, resulting in behavioural changes
of the recipient cells [7]. Additionally, EVs have been shown to be involved in a vast
number of pathological and physiological processes and have also been implicated in the
development a number of neurologi al and cardiovascular diseases [8]. However, in
the context of this current review it is significant that they are involved in almost every
st p of progression required for t e d velopment of carcinomas from the initial stage of the
primary tumour through to metastasis. Numerous studies have now confirmed that there
is a distinct difference between normal cell exosomes and cancer cell exosomes, both in
terms of their content and the rate at which they are released [9–11].
The content of tumour-derived EVs is diverse, can vary considerably and is largely
dependent on the cell of origin, in a similar manner to normal cell EVs. However, the
contents are highly bioactive and are able to elicit a considerable change in the activity of the
recipient cells. Some of the molecules carried by cancer-derived EVs include oncoproteins
and oncopeptides, as well as various RNA and DNA species that have the capacity to
instigate substantial changes to the tumour microenvironment. These changes often aid
the progression of tumour and metastasis development as EVs have been known to feature
a role in aspects of invasion and the maintenance of angiogenesis [12–14]. EVs have been
described to release factors involved in the epithelial to mesenchymal transition process via
stimulation of the epithelial cells, resulting in increased angiogenesis, extracellular matrix
remodelling and the loss of adhesion of tumour cells. This change in the microenvironment
encourages the release of tumour cells into circulation whereby they have the ability to
travel to alternative locations within the host and form metastases [14]. Additionally, EVs
have the ability to contribute towards the development of an aggressive disease phenotype
and the development of chemo and radio-therapy resistance [15]. Extensive evidence has
shown that one of the principal actions of cancer-derived EVs is to inhibit the anti-tumour
immune response. More specifically, studies have shown that cancer-derived EVs have
the ability to interrupt the recruitment, activation and functionality of a number of key
immune cells, including macrophages, regulatory T cells (Tregs), MDSCs, dendritic cells
and cytotoxic CD8+ T cells [2,16,17]. Evidently, EVs play a number of important roles that
make them excellent targets for novel immunotherapeutic techniques and for biomarker
mining [18].
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2. Role of HLA-I in Cells
Human leukocyte antigen I (HLA-I) and II (HLA-II) refers to the major histocom-
patibility complex (MHC) class I and class II proteins found in humans. Whilst HLA-II
molecules are restricted in expression and are typically only found on B cells and antigen
presenting cells and are responsible for the presentation of antigens to CD4+ T cells, HLA-I
molecules can be detected on the surface of almost all nucleated cells and are essential for
the activation of a CD8+ T cell response [19]. The critical role played by HLA-I antigen
presentation has been demonstrated where the possession of HLA-I heterogeneity, and also
carrying tumours with a high mutational burden, leads to significantly increased survival
times after checkpoint blockade therapy [20]. Tumour antigens are normally classed as ei-
ther tumour-specific antigens (TSA) which are expressed exclusively by tumour cells, or as
tumour-associated antigens (TAA), which can be expressed by normal cells but are known
to frequently be overexpressed in tumour tissue [21]. Eliciting a T cell response requires
the presentation of peptides which are generated primarily by proteasomal degradation in
the cytosol. Subsequent transport by transporter associated with antigen processing (TAP)
into the lumen of the endoplasmic reticulum and further trimming by proteolytic enzymes
such as endoplasmic reticulum aminopeptidase (ERAP) allows selected binding by HLA-I
molecules. These peptides can then be presented to antigen specific cytotoxic CD8+ T cells
(Figure 2), and in the context of cancer, lead to significant eradication of tumour cells. The
increased development and use of monoclonal antibody checkpoint inhibitor therapies
(directed against molecules such as PDL-1 and CTLA-4) have highlighted the benefits that
can result when the ability of CD8+ T cells to recognise cancer-related antigenic peptides
on the surface of cells is enhanced.




Figure 2. An outline of the human leukocyte antigen (HLA)/major histocompatibility complex 
(MHC) class I presentation pathway. The majority of the degradation of proteins destined for anti-
gen presentation by HLA-I occurs in the cytosol by the proteasome. These peptides are then trans-
located into the lumen of the endoplasmic reticulum (ER), by the transporter complex associated 
with antigen processing (TAP), where further trimming may occur. Peptides are then loaded onto 
HLA-I molecules with the help of chaperones and the resulting stable complexes are transported 
from the endoplasmic reticulum to the surface of the cell. The incorporation of HLA-I molecules 
into exosomes generated through the MVB pathway is thought to occur by internalisation of HLA-
I molecules from the cell surface. 
3. Immunotherapeutic Potential of EVs 
The presence of HLA-I molecules on the surface of EVs and the knowledge of their 
ability to present antigenic peptides to T cells has been well established [22–24]. Whilst 
the peptide ligandome presented by cell surface HLA-I molecules on cancer cells has been 
extensively investigated, the peptide ligandome on EVs is yet to be wholly defined. The 
fact that HLA-I molecules are frequently present on EVs released by cancer cells raises the 
possibility that they may be used as an additional or alternative source of material to char-
acterise and mine the HLA-I peptide ligandome relevant to anti-cancer responses. The 
presence of EVs in the bloodstream [25] further raises their potential to help characterise 
HLA-I relevant TAA or TSA of cancers that are difficult or impossible to biopsy to gener-
ate solid tissue generated ligandomes. A key question that then arises is whether or not 
the HLA-I peptide ligandome repertoire of EVs is a full representative duplicate of that of 
the cell surface. In our first study of EV HLA-I ligandomes, we utilised the Epstein-Barr 
virus-transformed B cell line Jesthom to address this question. HLA-I binding peptides 
were identified and analysed by carrying out small-scale isolations of MHC class I mole-
cules on EVs and comparing the resulting peptide repertoire to that of the cell surface [26]. 
A total of 516 peptides were eluted from both the cell surface and EVs that had predicted 
binding affinities to HLA-A*02:01 or HLA-B*27:05. Between the two groups of peptides 
Figure 2. An outline of the human leukocyte antigen (HLA)/major histocompatibility complex
(MHC) class I presentation pa hwa . The majority of the egradatio of proteins destined for antigen
presentation by HLA-I occurs in the cytosol by the proteasome. These peptides are then translocated
into the lumen of the endoplasmic reticulum (ER), by the transporter complex associated with antigen
processin (TAP), where further trimming may occur. P ptides are then loaded onto HLA-I molecules
with the help of chaperones and the resulting stable complexes are transported from the endoplasmic
retic lum to the surface of the cell. The incorporation of HLA-I molecules into exosomes generated
through the MVB pathway is thought t occur by internalisation of HLA-I molecules from the
cell surface.
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3. Immunotherapeutic Potential of EVs
The presence of HLA-I molecules on the surface of EVs and the knowledge of their
ability to present antigenic peptides to T cells has been well established [22–24]. Whilst
the peptide ligandome presented by cell surface HLA-I molecules on cancer cells has been
extensively investigated, the peptide ligandome on EVs is yet to be wholly defined. The
fact that HLA-I molecules are frequently present on EVs released by cancer cells raises
the possibility that they may be used as an additional or alternative source of material to
characterise and mine the HLA-I peptide ligandome relevant to anti-cancer responses. The
presence of EVs in the bloodstream [25] further raises their potential to help characterise
HLA-I relevant TAA or TSA of cancers that are difficult or impossible to biopsy to generate
solid tissue generated ligandomes. A key question that then arises is whether or not the
HLA-I peptide ligandome repertoire of EVs is a full representative duplicate of that of the
cell surface. In our first study of EV HLA-I ligandomes, we utilised the Epstein-Barr virus-
transformed B cell line Jesthom to address this question. HLA-I binding peptides were
identified and analysed by carrying out small-scale isolations of MHC class I molecules on
EVs and comparing the resulting peptide repertoire to that of the cell surface [26]. A total
of 516 peptides were eluted from both the cell surface and EVs that had predicted binding
affinities to HLA-A*02:01 or HLA-B*27:05. Between the two groups of peptides isolated,
there were no significant differences in either the resulting peptide-anchor motifs or the
range of predicted serotype-binding affinities. This study provided the first set of data to
confirm that EVs could effectively provide valuable information on the peptides present on
HLA-I and could be assessed as essentially duplicates of the cell surface HLA-I ligandome.
From this initial study we hypothesized that EVs could be of substantial use in cancer
studies with important antigenic peptides, including TAA and TSA, likely to be released
on EVs and therefore identifiable through mass spectrometry of their HLA-I ligandomes.
To directly address the above question, we have recently completed a study using
multiple cell lines representing breast cancer, melanoma and myeloma (Kumar et al.,
unpublished). Over 9000 peptides were characterised from the cell surface and EV HLA-I
ligandomes combined, and we were able to detect over 100 peptides in the EV ligandome
which were derived from tumour-associated proteins. In fact, over 5% of the peptides
detected in the EV HLA-I ligandome were derived from tumour antigens, indicating
their high relative abundance. Additionally, we identified a number of mutated peptides
that could be potential TSA. This new study shows direct evidence of the presence of
clinically relevant tumour-associated antigenic peptides in the HLA class I ligandome
present on EVs.
Our new extended dataset of peptides also allowed us to confirm an observation on
HLA-I ligand affinity made in our previous study on Jesthom cells. We classified peptide
ligands from cells and EVs as strong binders (predicted HLA-I binding affinity less than
100 nM) or weak binders (predicted HLA-I binding affinity between 100 nM and 1000
nM), respectively. A higher proportion of strong binding peptides were detected in the
EV ligandome compared to the cell ligandome (Figure 3). At present, we do not fully
understand why this should be the case, but one intriguing possibility is that the exosome
portion of the EVs has passaged through the MVB compartment within cells and may
have been subjected to an HLA-I peptide ‘editing’ environment that has not been fully
characterised. As a consequence, some of the lower affinity peptides may have been
lost. This also implies the possibility of MVB-derived unique peptides also being loaded
onto HLA-I in an exchange process within the MVB. Both of these possibilities require
further study.
The detection of TAA and potential TSA amongst the EV HLA-I ligandome raises
the question of whether such antigenic peptides could activate specific CD8+ T cells. If
so, cancer cell-derived EVs could be acting as decoys, causing ′off-target′ activation of
T cells away from the main tumour mass, limiting the anti-cancer response. There are
relatively few studies that describe the ability of HLA-I molecules on EVs to directly
promote the activity of cytotoxic CD8+ T cells, however, one study presented an increase
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in the interferon gamma secretion from purified CD8+ T cells when incubated with EVs
loaded with a selection of common antigenic viral peptides [27].




Figure 3. Predicted binding affinities for cell surface (CL) and extracellular vesicle (EV) HLA-I pep-
tides isolated from cancer cells lines. Based on predicted binding affinity by NetMHCpan 4.0 [28], 
HLA-I peptides were classified as strong binder (binding affinity less than 100 nM) or weak binders 
(binding affinity over 100 nM and up to 1000 nM) and the percentage of strong and weak binding 
peptides were plotted for both the cell and EV HLA-I ligandomes. The numbers in the columns 
indicate the percentages of each subset. The EV HLA-I peptide pool contained more peptides with 
predicted strong binding affinities compared to the cell surface HLA-I peptide pool. 
4. Challenges of Mapping the HLA-I Ligandome of EVs 
Defining the HLA-I ligandome of EVs usually involves the large-scale isolation of 
HLA-I molecules and mass spectrometric analysis of the resulting peptide pools. This is 
currently a major challenge as there are a number of variations in EV isolation protocols. 
In addition, defining the HLA-I ligandome of cancer-derived EVs holds additional chal-
lenges as the ratio of cancer-derived EVs to normal EVs will likely vary substantially and 
the number of peptides that result will therefore be low in number. The characterisation 
of biomarkers for cancer-specific EV would assist in the isolation of EV cancer subsets, for 
example by monoclonal antibody affinity purification, but again detection limits by cur-
rent mass spectrometric methods and limits to the amount of patient material that can be 
accessed pose significant challenges that need to be addressed. Typically, HLA class I pep-
tide isolation from both cell and EV lysates is carried out using immunoprecipitation, 
whereby the lysates are subjected to immunoaffinity chromatography, typically using the 
pan-HLA class I antibody W6/32 [28–30]. Preferably, the antibody is crosslinked to aga-
rose resins through covalent coupling to Protein A or Protein G. The HLA-I molecules are 
then eluted using an acid buffer, for example, TFA or acetic acid [31,32]. The released 
peptides are then enriched away from the HLA-I heavy chain and B2m proteins by C18-
matrix or other HPLC fractionation and elution with a moderate concentration of acetoni-
trile that favours elution of the peptides over HLA-I components. Alternatively, ultrafil-
tration that relies on the application of a molecular weight filter can be applied to obtain 
a sub-3000 Dalton fraction [28,30]. Peptide sequences are identified by liquid chromatog-
raphy-coupled tandem mass spectrometry (LC-MS/MS), whereby the sequencing is typi-
cally achieved through the use of collision induced dissociation (CID) or by higher energy 
collisional dissociation (HCD) [29]. The resulting fragmented peptide ions can then be 
searched using various automated search databases, and additionally can be applied to 
de novo analysis to identify the peptide sequences. These peptide sequences can then be 
searched against a number of databases to source their matched proteins and potential 
TAA and TSA can be identified [29,31]. In recent years it has also been recognised that a 
substantial proportion of HLA-I ligands are in fact generated from non-canonical sources 
Figure 3. Pre icte binding affinities for cell surface (CL) and extrac llular vesicle (EV) HLA-I
peptides isolated from cancer cells lines. Based on predicted binding affinity by NetMHCpan 4.0 [28],
HLA-I peptides were classified as strong binder (binding affinity less than 100 nM) or weak binders
(binding affinity over 100 nM and up to 1000 nM) and the percentage of strong and weak binding
peptides were plotted for both the cell and EV HLA-I ligandomes. The numbers in the columns
indicate the percentages of each subset. The EV HLA-I peptide pool contained more peptides with
predicted strong binding affinities compared to the cell surface HLA-I peptide pool.
4. Challenges of Mapping the HLA-I Ligandome of EVs
Defining the HLA-I ligandome of EVs usually involves the large-scale isolation of
HLA-I molecules and mass spectrometric analysis of the resulting peptide pools. This is
currently a major challenge as there are a number of variations in EV isolation protocols. In
addition, defining the L -I ligando e of cancer-derived EVs holds additional challenges
as the ratio of cancer-derived EVs to normal EVs will likely vary substantially an the
er f peptides that result will therefore be low i number. The characterisation
of biomarkers for canc r-specific EV would assist in the isolation of EV canc r subsets,
for xample by monoclonal antibod affinity purification, but again detection limits by
current mass sp ctro ric methods and limits to the amount of patient material that can
be accessed pose significant challenges that n e to be addressed. Typically, HLA class I
peptide isolation from both cell and EV lysates is carried out using immunoprecipitation,
whereby the ly ates are subjec ed to immunoaffinity chromatography, typically using the
pan-HLA class I antibody W6/32 [29–31]. Preferably, the antibody is cro slinked to agarose
resins through covalent coupling to Protein A or Protein G. The HLA-I molecules are then
eluted using an acid buffer, for example, TFA or acetic ac d [32,33]. The released peptides
are then enriched away from the HLA-I heavy chain and B2m proteins by C18-matrix or
othe HPLC fractionati nd elution with a moderate concentration of acetonitrile that
favours el tion of the peptides over HLA-I components. Alternatively, ultrafiltration that
relies on the application of a molecular weight filter can be applied to obtain a sub-3000
Dalton fraction [29,31]. Peptide sequences are identified by liquid chromatography-coupled
tandem mass spectrometry (LC-MS/MS), whereby the sequencing is typically achieved
through the use of collision induced dissociation (CID) or by higher energy collisional
dissociation (HCD) [30]. The resulting fragmented peptide ions can then be searched using
various automated search databases, and additionally can be applied to de novo analysis
to identify the peptide sequences. These peptide sequences can then be searched against a
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number of databases to source their matched proteins and potential TAA and TSA can be
identified [30,32]. In recent years it has also been recognised that a substantial proportion
of HLA-I ligands are in fact generated from non-canonical sources such as non-coding
regions and from peptide-splicing events occurring within the proteasome [34–36]. This
emerging picture of neoantigens will require the adoption and use of novel databases to
ensure the full range of the HLA-I ligandome is mapped.
Whilst the field of large-scale immunopeptidomics is rapidly evolving, there is sub-
stantial room and broad scope for standardising protocols wherever possible amongst
the many laboratories generating HLA-I peptidome data. If the ideals of the Human
Immunopeptidome Project are to be realised [37], where immunopeptidome data has been
proposed to be useful in the same manner as proteome and genome wide association
studies (GWAS), a higher degree of standardisation will be a requisite. Typical current
issues with mass spectrometric instrumentation, over and above sample preparation, can
include sensitivity, resolving power and acquisition speeds. Sensitivity is a particular issue
for smaller samples, which would be the typical situation for many clinical samples, as only
the most abundant and easily detected peptides are identified [38]. There are also a number
of restrictions beyond the isolation of peptides related to the analysis and the ability to
match peptides to proteins effectively and identify antigens of interest, largely due to a
lack of complete databases and efficient algorithms for searching the raw LC-MS/MS data.
In addition, the methodology of data independent acquisition (DIA) has also been utilised
to supplement the more traditional data dependent acquisition (DDA) modes and may
prove to be of significant value. Thus, it is likely that the efficiency and accuracy of future
immunopeptidomic studies will rely heavily on the establishment of simple and refined
protocols aimed at reducing the loss of peptides, further development of DIA protocols
to achieve more sensitivity and reproducibility, and on the continuous improvement of
instrument sensitivity. Ultimately, mass spectrometric characterisation of peptides may be
supplemented with novel methods of single peptide sequencing that could, in combination,
fully map the entire immunopeptidome of any given sample [39–41].
5. Potential Manipulation of EVs
Tumour-derived exosomes could be ideal candidates for an efficient tumour antigen
delivery system that would result in the activation of cytotoxic lymphocytes and enhance
anti-tumour protection. EVs are an attractive option as they would be readily available
and easily accessible through a number of standard biological samples such as blood,
urine and cerebrospinal fluid. The peptidomic information that could be retrieved from
EVs could provide valuable insight into the immune-modulatory actions being exercised
by tumour cells. In theory, similar repertoires of peptides and associated TAA/TSA
should be observed on the MHC class I molecules of EVs derived from the same cancer
cells. As a result, patterns of peptide expression could lead to diagnostic and prognostic
biomarkers and could additionally provide targets for a form of immune therapy or cancer
vaccine [18,42–44]. The search for appropriate cancer vaccines is a continuously developing
field [45]. An effective cancer vaccine requires the ability to elicit an immune response
characterised by tumour antigen-specific cytotoxic T-lymphocytes that are capable of
recognising and acting upon residual or metastatic tumour cells. In effect, the ideal cancer
vaccine would enhance the presentation of antigens by antigen presenting cells, resulting
in the promotion of an effective anti-tumour immune response. Current challenges that are
associated with the search for an effective cancer vaccine include a lack of available tumour
antigens that are both relevant and known to invoke an immune response, as well as a lack
of effective delivery or targeting system. Defining the HLA-I ligandome of EVs derived
from cancer cells could provide the specific tumour antigens that would be ideal targets for
a cancer vaccine.
Thus far, research has focused on the loading of dendritic cell-derived EVs to deliver
tumour antigens as they are assumed to be able to effectively maintain their homeostatic
functions of presenting TAA and promoting a TAA-specific immune response. A number of
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clinical trials have been conducted over the years using TAA-loaded dendritic cell-derived
EVs, with varying results [46,47]. One early phase I clinical study loaded melanoma-
associated tumour antigens (MAGEs) onto dendritic cell-derived EVs and applied them
therapeutically to advanced melanoma patients with MAGE3+ disease characterisation. Of
the 15 patients involved in the study, one elicited a response, one elicited a minor response
and two elicited disease stabilisations, although no MAGE-specific T cell responses were
recorded [46]. A different group conducted a similar study on patients diagnosed with
advanced MAGE+ non-small cell lung cancer and found that over a third of the participants
effectively developed a MAGE-specific immune response as a result of the therapeutic
application of MAGE loaded dendritic cell-derived EVs [47]. Another Phase I clinical
trial using the vaccination of dendritic cell-derived exosomes in patients diagnosed with
advanced melanoma resulted in the successful promotion of activation and proliferation
of natural killer cells [48]. Additionally, in 2016, Besse and colleagues also confirmed
that dendritic cell-derived exosomes improved the activity of natural killer cells through
the results of a Phase II clinical trial on patients diagnosed with non-small cell lung
cancer [49]. The adaptation of cancer vaccines to target patient TAA or TSA would be
a form of personalised immune therapeutics involving the formation and injection of
synthetic versions of the mutated peptides loaded on to extracellular vesicles. Whilst the
therapeutic use of EVs as a targeted delivery system has only been implemented in early
trials, the results collected thus far have established that the use of EVs as vectors is a safe
and viable option, with substantial potential in manipulating and enhancing the immune
response in a variety of cancers.
6. Conclusions
The essential role of HLA-I in the presentation of peptides to CD8+ T cells provides
a promising target for immune therapies, especially in the field of cancer. Additionally,
the repertoire of peptides expressed on the HLA-I ligandome of cancer-derived EVs could
provide a rich source of information that could be utilised to develop innovative and novel
approaches to both personalised immune therapy and cancer diagnostics. Additional
studies into EV HLA-I ligandomes, investigating the effects of variables such as the stage of
cancer, location of primary and metastatic lesions, and the impact of treatment regimens on
the resulting immunopeptidome of EVs, will further our understanding of how the peptide
landscape changes throughout the course of the disease and could potentially define the
most favourable methods or timepoints to intervene. Recent literature also demonstrates
the need to establish standardized approaches to identifying HLA-I peptides to reduce
variabilities between peptidomic studies in both sample preparations and the subsequent
mass spectrometric analysis of immunopeptidomes.
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